NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

A look at robotic surgery proliferation in Denmark

Frederik Joelving, who once did outstanding work for ReutersHealth in the U.S., recently published a piece on robotic surgery in Politiken, a major newspaper in Denmark.

A rough translation of the way the article concluded:

“It may be difficult to reverse (the proliferation trend) if the large randomized trials that other countries are doing should give low marks to the da Vinci system. … Consultant Christian Gluud of the Copenhagen Trial Unit at the University Hospital and an expert in evidence-based medicine, believes that the lack of regulation has left patients in the lurch. “The talks can be held for days about all the damage that has been observed by things slipped through the market without being properly investigated,” he said . “There is a patient safety issue that we have not sufficiently mastered.”

Joelving wrote to me:

“What’s interesting is that even though our healthcare system is publicly funded, the development here is largely parallel to what’s been happening in the US: With hospitals competing to take the lead in robotic surgery and using dubious claims to market the technology, it has now become virtually impossible to have an open (let alone traditional laparoscopic) prostatectomy in most parts of the country.

So far, Denmark — a country of 5.5 million — has bought da Vinci equipment for 44 million US$, and the reimbursement for each robotic surgery is between 5000 and 10000 US$ higher than for the traditional approach. What’s more, all except one university-affiliated hospitals have stopped teaching open/laparoscopic prostate surgery. As one of my sources said, What happens when something goes wrong during a robotic surgery and you have to convert?”

The global march of the robots continues.

—————————

Follow us on Twitter:

https://twitter.com/garyschwitzer

https://twitter.com/healthnewsrevu

and on Facebook.

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.